학술논문
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
Document Type
Article
Author
Ramasamy, M.N.; Aley, P.K.; Bibi, S.; Pollard, A.J.; Kelly, E.J.; Swanson, P.A.; Jepson, B.; Villafana, T.; Seegobin, S.; Matthews, S.; Vekemans, J.; Pangalos, M.N.; Green, J.A.; Dargan, P.I.; Martinez-Alier, N.; Payne, R.; Libri, V.; Adam, M.; Church, A.; Khan, M.; Townsend, G.T.; Lambe, T.; Wildman, E.; Rampling, T.; Morris, S.; Shoemaker, K.; Aksyuk, A.; Padilla, M.G.; Roe, T.; Petropoulos, C.J.; Wrin, T.; Colton, H.; Bisnauthsing, K.; Smith, C.; Leeman, L.; Galloway, J.; Nagra, D.; Lazarus, R.; Penciu, F.; Hunter, E.; Sahdev, A.; Turner, D.; Royal, S.; Uriel, A.; Ustianowski, A.; Moran, E.; Green, C.; Desai, A.; Lakeman, N.; Moore, P.; Whittington, A.; Kobielusz Gembala, I.; Konieczny, M.
Source
In: The Lancet Microbe . (The Lancet Microbe, November 2023, 4(11):e863-e874)
Subject
Language
English
ISSN
26665247